keyboard_arrow_up

Market research on overview of psoriasis unveils a host of opportunities

Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients pain, function, and quality of life. Approved biologics fill in a critical unmet need of limited efficacy of DMARDs; however, as in most cases one drug does not fit the bill for all the patients.

The lack of targeted immune therapies other than TNF- inhibitors in Psoriasis signals opportunities for drug developers to bring agents to market that offer treatment alternatives (Anti-IL-17, IL-13, JAK, PDE4 inhibitors, etc). Pfizer launched the first oral Rheumatoid Arthritis (RA) drug -Xeljanz (tofacitinib/ CP-690,550, JAK 1/3 inhibitor) in 2012 for pts with moderately to severely active RA who are inadequate responder or intolerant to Methotrexate (MTX) at a price almost at par with biologics.

In the last couple of years, the face of healthcare has been changing due to challenges - quality and its affordability and accessibility to the providers and patients. We believe there is an ample room for an efficacious affordable therapy to tap the mild to moderate RA pts population where biologics have not made a dent and expect few potential launches in 2014-15 (OTEZLA - apremilast, Xeljanz - tofacitinib) and onwards. In this report, we highlight the novel targets - oral, injectables, and topical drugs in the pipeline for the treatment of Psoriasis, compare their clinical trials data, and their commercial potential!

TABLES 

Table # Title Pg. No. 
1 Approved/ Marketed Products 3 
2 A. Psoriasis Pipeline: Small Molecules - Oral/ Injectable 
B. Psoriasis Pipeline: Topical 5-6 
3 Psoriasis Pipeline: Biologics 6 
4 Select Late- & Mid-Stage Pipeline: Plaque Psoriasis 8-9 
5 Select Late- & Mid-Stage Pipeline: Psoriatic Arthritis 9 
6 Ixekizumab: Phase III Clinical Trial Designs 17 
7 Brodalumab: Phase III Clinical Trial Designs 18 
8 Clinical Data Comparison: Plaque Psoriasis - Biologics 23 
9 A. Tofacitinib: PASI Improvement from Baseline 
B. Tofacitinib: Improvement in Quality-of-Life (QOL) Measures 26 
10 Other Targets in Clinical Development for RA 31 
11 Genes Associated with Psoriasis Susceptibility 42 
12 Competitive Landscape: Plaque Psoriasis 51-52 
13 Competitive Landscape: Psoriatic Arthritis 53-54

To order this report:

Email: support@researchonglobalmarkets.com

US:  +1 866 325 7446

UK: +44 203 514 2363

India: +91 22 4098 7600

SOURCE:  Researchonglobalmarkets.com

RELATED LINK: Therapeutic class overview of psoriasis | Research Reports